AstraZeneca Launches Sunvozertinib (ZEGFROVY) in the US for EGFR exon20ins NSCLC
Start here
On October 23, 2026, AstraZeneca announced the commercial launch of ZEGFROVY (sunvozertinib tablets) in the United States. The drug, independently developed by Dizhe Pharmaceutical, treats adults with locally advanced or metastatic non-small cell lung cancer harboring confirmed EGFR exon20 insertions whose disease progressed on or who cannot tolerate prior platinum-based chemotherapy. It is described as the only approved oral single-agent targeted therapy for such patients after platinum chemotherapy. The second-line and later monotherapy indication is now approved in both China and the US. Supplemental applications for first-line treatment of EGFR exon20ins NSCLC have been accepted for review by both China's CDE and the FDA, and those first-line decisions remain open, as does whether AstraZeneca's acquisition was a precondition for US commercialization.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickAstraZeneca Announces US Approval of Sunvozertinib (ZEGFROVY) for EGFR exon20ins NSCLC
On October 23, 2026, AstraZeneca announced that ZEGFROVY (sunvozertinib tablets), independently developed by Dizhe Pharmaceutical, is officially launched in the United States. The drug treats adults with locally advanced or metastatic NSCLC with confirmed EGFR exon20ins whose disease progressed on or who cannot tolerate prior platinum-based chemotherapy.
- mp.weixin.qq.comDizhe's ZEGFROVY Launches in the US as First-Line Application Accepted by FDA and CDE
AstraZeneca announced that sunvozertinib (ZEGFROVY), developed by Dizhe Pharmaceutical, is now officially launched in the United States for adults with locally advanced or metastatic NSCLC harboring EGFR exon20ins whose disease progressed on or who are intolerant to prior platinum-based chemotherapy. The drug's second-line and later monotherapy indication is approved in both China and the US, and its new application for first-line treatment of EGFR exon20ins NSCLC has been accepted by both CDE and the FDA.
- mp.weixin.qq.comPickSunvozertinib (ZEGFROVY) Launches in the US for EGFR exon20ins Non-Small Cell Lung Cancer
On October 23, 2026, Dizhe Pharmaceutical (Dizhe Cayman) announced that its global strategic partner AstraZeneca has commercially launched sunvozertinib tablets (ZEGFROVY) in the United States. The drug treats adults with locally advanced or metastatic NSCLC harboring confirmed EGFR exon20ins whose disease progressed on or who cannot tolerate prior platinum-based chemotherapy. The second/later-line monotherapy indication is now approved in both China and the US, and the first-line supplemental application has been accepted for review by the CDE and the FDA.
- mp.weixin.qq.comAstraZeneca Launches Sunvozertinib (ZEGFROVY) in the United States
On October 23, 2026, Dizhe (Dizal) announced that its global strategic partner AstraZeneca has officially launched sunvozertinib (ZEGFROVY) in the United States. The drug treats adults with locally advanced or metastatic NSCLC with confirmed EGFR exon20ins whose disease progressed on or who are intolerant to platinum-based chemotherapy. Its first-line indication application has been accepted by both CDE and FDA.
- mp.weixin.qq.comWould Sunvozertinib Still Be Unable to Launch Commercially in the US Without AstraZeneca's Acquisition?
AstraZeneca announced on October 22, 2026 that sunvozertinib is officially launched in the United States, but the source did not state whether the acquisition was a precondition for commercialization. The drug treats previously treated EGFR exon 20 insertion-mutated NSCLC; the article says it is the only approved oral single-agent targeted therapy for such patients after platinum chemotherapy.
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 24 19:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.